Eledon Pharmaceuticals (NASDAQ:ELDN) Given Buy Rating at HC Wainwright

Key Points

• HC Wainwright has restated a "buy" rating for Eledon Pharmaceuticals (NASDAQ: ELDN) with a target price of $9.00, suggesting a potential upside of 247.49% from the current stock price.
• Despite the buy rating from HC Wainwright, other analysts like Zacks Research and Wall Street Zen have issued lower ratings, leading to a consensus rating of "Moderate Buy".
• Eledon Pharmaceuticals reported a quarterly earnings beat with ($0.13) earnings per share, outperforming expectations of ($0.23) per share.

HC Wainwright reaffirmed their buy rating on shares of Eledon Pharmaceuticals (NASDAQ:ELDN - Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright also issued estimates for Eledon Pharmaceuticals' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.31) EPS.

Several other analysts have also weighed in on ELDN. Wall Street Zen lowered Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Craig Hallum assumed coverage on Eledon Pharmaceuticals in a report on Friday, July 25th. They issued a "buy" rating and a $12.00 price objective for the company. Finally, Zacks Research lowered Eledon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday, August 18th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.00.

Eledon Pharmaceuticals Stock Up 3.8%

ELDN stock traded up $0.10 during trading on Tuesday, reaching $2.71. 884,551 shares of the company's stock were exchanged, compared to its average volume of 639,704. Eledon Pharmaceuticals has a 1-year low of $2.38 and a 1-year high of $5.54. The company's fifty day moving average price is $3.05 and its 200-day moving average price is $3.17. The firm has a market cap of $162.27 million, a PE ratio of -2.32 and a beta of -0.12.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.10. As a group, sell-side analysts expect that Eledon Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. raised its position in Eledon Pharmaceuticals by 96.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock valued at $10,513,000 after buying an additional 1,254,298 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in Eledon Pharmaceuticals during the fourth quarter valued at $4,848,000. AWM Investment Company Inc. acquired a new position in Eledon Pharmaceuticals during the fourth quarter valued at $4,534,000. Point72 Asset Management L.P. acquired a new position in Eledon Pharmaceuticals during the fourth quarter valued at $4,511,000. Finally, Woodline Partners LP raised its position in Eledon Pharmaceuticals by 98.3% during the fourth quarter. Woodline Partners LP now owns 1,671,822 shares of the company's stock valued at $6,888,000 after buying an additional 828,930 shares during the period. Hedge funds and other institutional investors own 56.77% of the company's stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).